Meeting
2023 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).
Authors
Benjamin Adam Weinberg
Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Benjamin Adam Weinberg , Martin Gutierrez , Anteneh A. Tesfaye , Ming Tony Tan , Marcus Smith Noel , Aiwu Ruth He , Reetu Mukherji , John Marshall , Jennifer Gleim , Kerrie Bouker , Louis M. Weiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05558982
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4194)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4194
Abstract #
TPS4194
Poster Bd #
503b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
First Author: Benjamin Adam Weinberg
Poster
2018 Gastrointestinal Cancers Symposium
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
First Author: Manuel M. Hidalgo
Poster
2023 ASCO Annual Meeting
Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Anser Ali Abbas
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.
First Author: Ben George